| Helping Young People With Testicular Cancer Using Virtual and Extended Reality (NCT07571499) | Gustave Roussy, Cancer Campus, Grand Paris | 2027-01-04 |
| Adjuvant Trial in Pancreatic Neuroendocrine Tumors (NCT07591493) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-09-01 |
| Carboplatin-Enhanced Therapy in BRCA-Mutated or Neuroendocrine-Differentiated Aggressive Metastatic Castration-Sensitive Prostate Cancer (NCT07591467) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-09-01 |
| Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases (NCT07544225) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-09-01 |
| Preliminary Clinical Feasibility Study of a Medical Device Enabling Brain Access Using Microbubble-Enhanced Sonication (NCT07754006) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-09-01 |
| KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer (NCT07622017) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-07-01 |
| Survival Without Persistent Limiting Toxicity: Real Life Prospective Cohort of Advanced Neuroendocrine Tumor (NCT07471425) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-06-01 |
| Cohort of Patients With Chronic Myelomonocytic Leukemia (NCT07512882) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-05-05 |
| Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer (NCT07436312) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-05-04 |
| Trial to Evaluate Nonavalent HPV Vaccine as a Secondary Prevention in Patients Treated for Human Papilloma Virus Related High-grade Squamous Intraepithelial Lesions (NCT07431502) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-05-01 |
| Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance (NCT07483983) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-03-25 |
| Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (NCT06907095) | Gustave Roussy, Cancer Campus, Grand Paris | 2026-03-16 |
| Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer (NCT06787118) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-12-01 |
| Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (NCT07001618) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-11-17 |
| A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer (NCT07159451) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-10-06 |
| A Study to Determine the Efficacy of a Digital Self-management Support Tool to Improve the Quality of Life During Adjuvant HOrmonal Therapy for Patients With Early Breast Cancer (NCT06781996) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-09-09 |
| First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients. (NCT06840782) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-09-09 |
| Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) (NCT07016230) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-07-02 |
| Study on the Effectiveness and Comfort of Innovative Solutions for the Internal Transport of Patients in Wheelchairs in a Hospital Setting (NCT06902883) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-06-16 |
| Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma (NCT06934057) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-05-16 |
| Analysis of Risk Factors for Hearing Loss in Survivors of Cancer Occurred During Childhood, Adolescence or Young Adulthood (NCT06957132) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-05-01 |
| tislelizUMaB in canceR Patients With molEcuLar residuaL Disease (NCT06332274) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-04-16 |
| Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures (NCT06713798) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-30 |
| Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NCT06116578) | Gustave Roussy, Cancer Campus, Grand Paris | 2025-01-01 |
| Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma (NCT06813573) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-09-30 |
| Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer (NCT06439888) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-07-11 |
| A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (NCT06508216) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-07-05 |
| Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer (NCT06712472) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-06-26 |
| CARE1 Pragmatic Clinical Trial (NCT06364631) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-04-12 |
| Evaluation Contact X-ray Brachytherapy for Rectal Preservation in Intermediate Substage Rectal Adenocarcinoma (NCT06402864) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-03-26 |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (NCT06298084) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-03-21 |
| PROACT is a Prospective Master Protocol for a Cohort Study Focused on Evaluating the Implementation of Integrated Proactive Supportive Care Pathways at Gustave Roussy (NCT06479057) | Gustave Roussy, Cancer Campus, Grand Paris | 2024-01-11 |
| Preoperative Radiotherapy And ASTX660 in Rectum Cancer (NCT05912075) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-12-19 |
| Thromboprophylaxis in Good and Intermediate Prognosis Advanced Germ Cell Tumors (NCT05874063) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-10-17 |
| Therapeutic Vaccine in Patients With Human Papillomavirus HPV-positive Oropharyngeal Cancer (NCT06007092) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-07-31 |
| Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma (NCT05830084) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-06-16 |
| Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant (NCT05889585) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-05-31 |
| Engineering Immune Organoids to Study Pediatric Cancer (NCT05890781) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-05-12 |
| Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors (NCT05705687) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-05-05 |
| A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (NCT05119010) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-03-24 |
| Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (NCT05692999) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-03-20 |
| Clinical Investigation Evaluating Safety and Efficacy of Selective Intra-arterial 166Holmium Radiation Therapy in Combination With Atezolizumab and Bevacizumab for Non Resectable Hepatocellular Carcinoma (NCT05705791) | Gustave Roussy, Cancer Campus, Grand Paris | 2023-02-07 |
| Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C (NCT05631249) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-12-13 |
| Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 (NCT05476939) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-09-29 |
| MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 (NCT05691608) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-09-09 |
| Implementing Precision Medicine in cOmmunity HospiTALs (NCT05283044) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-06-29 |
| An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors (NCT05481502) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-06-08 |
| Optimization of an Online Stepwise Therapeutic Device Based on a Cognitive-behavioral Approach for Cancer Patients With Insomnia (NCT05977062) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-02-25 |
| Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard Therapy (NCT05180006) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-02-24 |
| Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers (NCT05267912) | Gustave Roussy, Cancer Campus, Grand Paris | 2022-01-19 |
| Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer (NCT04940325) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-05-12 |
| Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (NCT04965766) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-05-11 |
| Gustave Roussy Cancer Profiling (NCT04932525) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-05-10 |
| Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (NCT04779151) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-04-07 |
| Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence (NCT05071001) | Gustave Roussy, Cancer Campus, Grand Paris | 2021-03-19 |
| Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery (NCT04842162) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-12-15 |
| Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma (NCT04823403) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-11-13 |
| Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months (NCT04826198) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-10-05 |
| Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis (NCT04826432) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-09-03 |
| Motivating to Exercise and Diet, and Educating to Healthy Behaviors After Breast Cancer (NCT04304924) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-06-17 |
| Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (NCT04270864) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-04-10 |
| Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults (NCT04477681) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-04-09 |
| Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients (NCT04341207) | Gustave Roussy, Cancer Campus, Grand Paris | 2020-04-03 |
| High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (NCT04221035) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-11-05 |
| Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma (NCT04267146) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-07-15 |
| USE OF 18FDG PET-CT TO PREDICT THE RESPONSE OF MANDIBULAR OSTEORADIONECROSIS TO THE PENTOCLO PROTOCOL WITH DOCUMENTED ANTIBIOTHERAPY (NCT04826445) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-06-11 |
| Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer (NCT03819101) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-06-06 |
| Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (NCT03982121) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-06-04 |
| Classical Monocyte Kinetics in Chronic Myelomonocytic Leukemia (NCT04775121) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-05-13 |
| Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (NCT04276376) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-04-12 |
| Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NCT03703050) | Gustave Roussy, Cancer Campus, Grand Paris | 2019-01-02 |
| Predictive Markers of Immune-related Adverse Events in Patients Treated With Immune Stimulatory Drugs (NCT03984318) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-12-12 |
| Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer (NCT03596281) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-12-05 |
| Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (NCT03165292) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-10-01 |
| Low-level Laser Therapy in the Prevention of Chemotherapy-induced Mucositis in Children and Young Adults (NCT03983369) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-08-29 |
| Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (NCT03612791) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-08-13 |
| ESTIMation of the ABiLity of Prophylactic Central Compartment Neck Dissection to Modify Outcomes in Low-risk Differentiated Thyroid Cancer (NCT03570021) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-08-08 |
| Two Chemotherapy Regimens Plus or Minus Bevacizumab (NCT03351296) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-06-26 |
| Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer (NCT03613194) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-06-25 |
| IMRT and Primary Transoral Surgery in the Treatment of Squamous Cell Carcinomas (NCT04224389) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-06-22 |
| Study of Coronary Calcium Score as a Marker of Post-radiation Vascular Dysplasia in Adults Treated During Childhood for Cancer With Mediastinal Irradiation (NCT03604627) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-06-14 |
| Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma (NCT03313206) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-05-28 |
| AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy (NCT03308604) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-05-17 |
| Video-Based Cognitive Behavioral Therapy for Insomnia in Adults Cancer Patients and Survivors (NCT03981666) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-05-04 |
| Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma (NCT03406247) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-02-12 |
| Discovery of Microbiome-based Biomarkers for Patients With Cancer Using Metagenomic Approach (NCT04567446) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-01-22 |
| Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma (NCT03519048) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-01-17 |
| Evaluation of HPV OncoTect ™ for the Etiological Diagnosis of HPV-induced Oropharyngeal Cancers (NCT03604588) | Gustave Roussy, Cancer Campus, Grand Paris | 2018-01-17 |
| Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (NCT03244956) | Gustave Roussy, Cancer Campus, Grand Paris | 2017-12-27 |
| A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer (NCT03314324) | Gustave Roussy, Cancer Campus, Grand Paris | 2017-11-29 |
| Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab (NCT03212651) | Gustave Roussy, Cancer Campus, Grand Paris | 2017-10-17 |